I-Ozempic eyengeziwe isho ukulawula okungcono kwesifo sikashukela sohlobo 2

I-Novo Nordisk namuhla imemezele ukuthi i-US Food and Drug Administration (FDA) igunyaze umthamo we-2 mg we-Ozempic® (semaglutide), i-analog efana ne-peptide-1 (GLP-1) ye-glucagon kanye ngesonto ekhonjiswa kanye nokudla nokuzivocavoca. ukuthuthukisa ushukela egazini kubantu abadala abanesifo sikashukela sohlobo 2 nokunciphisa ingozi yezenzakalo ezinkulu zenhliziyo nemithambo yegazi njengokuhlasela kwenhliziyo, unhlangothi noma ukufa kwabantu abadala abanesifo sikashukela sohlobo 2 nesifo senhliziyo esaziwayo.2 I-Ozempic® ayisona isidakamizwa sokwehlisa isisindo, kodwa ingase ukusiza abantu ukunciphisa isisindo. I-Ozempic® izotholakala ngemithamo yokwelapha emithathu (0.5 mg, 1 mg, no-2 mg) ukuze isize abantu abanesifo sikashukela sohlobo 2 bafinyelele umgomo wabo kashukela (A1C), manje okuhlanganisa nalabo abane-A1C ephakeme abangakwazi ukuhlangabezana nezidingo zabo. Ithagethi ye-A1C.

Ohlelweni lokuhlolwa komtholampilo lwesigaba sesi-3 se-Ozempic® SUSTAIN, abantu abangafika ku-73% abanesifo sikashukela sohlobo 2 abalashwe nge-Ozempic® 1 mg behlisa ushukela wabo wasegazini futhi bafinyelela kumgomo we-American Diabetes Association ongu-<7%.3-5 Naphezu kwalokhu, kukhona basengabantu abangekho ezingeni labo likashukela egazini.1,4-10 Ozempic® 2 mg isiza labo abadinga ukulawulwa okwengeziwe kwe-glycemic futhi iyindlela ebalulekile ezigulini nabahlinzeki ekwelapheni okuqhubekayo kohlobo lwesifo sikashukela sohlobo 2.

“Uhlobo lwesifo sikashukela sohlobo 2 luyisifo esiyinkimbinkimbi esingathuthuka ngokuhamba kwesikhathi noma ngabe umuntu usiphethe ngemithi, ngokudla nangokuvivinya umzimba,” kusho uDkt Juan Pablo Frias, umqondisi wezokwelapha weVelocity Clinical Research, eLos Angeles kanye nomphenyi oyinhloko we-SUSTAIN FORTE, ukuhlolwa komtholampilo kwesigaba sesi-3 esisekela ukugunyazwa kwe-Ozempic® 2 mg. “Ngenxa yokuphepha nokusebenza ngempumelelo kwayo okuqinisekisiwe, i-Ozempic® isiza ekulawuleni ushukela wegazi futhi inikezela ngokunciphisa okukhulu kwengozi yezenzakalo zenhliziyo nemithambo yegazi kubantu abadala abanesifo sikashukela sohlobo 2 nesifo senhliziyo esaziwayo, futhi ingasiza iziguli eziningi ukuba zehlise isisindo. Ngomthamo ongu-2 mg, sinenketho eyengeziwe ukuze iziguli zikwazi ukuhlala ekwelapheni okufanayo ngemithi ngisho noma ushukela wegazi udinga ukushintshwa.”

Ocwaningweni lwe-SUSTAIN FORTE, abantu abanesilinganiso sokuqala se-A1C esingu-8.9% abalashwe nge-Ozempic® 2 mg bathole ukwehla okuphawulekayo kwezibalo nokuphakeme kushukela osegazini ngo-2.1% ngeviki 40 uma kuqhathaniswa no-1.9% nge-Ozempic® 1 mg (P<0.01 ).1 Ocwaningweni olufanayo, abantu abanesisindo sokuqala esiyisilinganiso esingu-219 lb abalashwe nge-Ozempic® 2 mg behle isisindo esingu-14.1 lb uma kuqhathaniswa nokuncipha kwesisindo esingu-12.5 lb nge-Ozempic® 1 mg; umehluko wawungabalulekile ngokwezibalo. Kuyo yomibili imithamo ye-Ozempic®, azikho izimpawu ezintsha zokuphepha ezikhonjiwe.1 Izehlakalo ezimbi ezazivame kakhulu kwakuwukuthumbulwa kwesisu.1 Ukusabela okungathandeki emathunjini kwenzeka kaningi ezigulini ezithola i-Ozempic® 2 mg (34.0%) vs Ozempic® 1 mg (30.8% ).1

“I-Ozempic® isiza iNovo Nordisk ukuthi ishintshe ekunakekelweni kwesifo sikashukela, njengoba abantu abangaphezu kwesigidi abanesifo sikashukela sohlobo 2 e-United States belashwa nge-Ozempic®,” kusho uDoug Langa, iphini likamongameli omkhulu, eNorth America kanye nomongameli. ye-Novo Nordisk Inc. “Nge-Ozempic® manje etholakala ngamandla ahlukahlukene okudosa, sinethemba lokuthi singakwazi ukusiza abantu abengeziwe abanesifo sikashukela sohlobo 2 abadinga ulwazi olwengeziwe lokulawula ushukela egazini lezinzuzo ze-Ozempic®.”  

I-Novo Nordisk ilindele ukwethula i-Ozempic® 2 mg e-United States maduze. I-Ozempic® 2 mg ivunywe yi-Swiss Medic ngoSepthemba 2021 ilandelwa yi-Health Canada kanye ne-European Medicines Agency ngoJanuwari 2022.